Neurological course of long-term surviving patients with SCLC and anti-Hu syndrome.
Patients with small-cell lung cancer (SCLC) have a poor prognosis with a three year survival rate of 4%. Our report concerns three patients with histologically proven SCLC and anti-Hu associated paraneoplastic neurological syndrome who have survived for 11 in two cases and 16 years respectively. The patients showed progressive deterioration which was only partly beneficially modulated by steroid therapy or tumor treatment, even in the cases with complete tumor remission.
Poepel
A
A
University of Bonn, Department of Epileptology, Sigmund-Freud-Str. 25, Bonn, Germany. annkathrin.poepel@swissepi.ch
Jarius
S
S
Heukamp
L C
LC
Urbach
H
H
Elger
C E
CE
Bien
C G
CG
Voltz
R
R
D018288:Carcinoma, Small Cell / Q000150:complications / Q000276:immunology / Q000401:mortality; D051959:ELAV Proteins / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000276:immunology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D020361:Paraneoplastic Syndromes, Nervous System / Q000150:complications / Q000276:immunology / Q000401:mortality; D012189:Retrospective Studies
D051959:ELAV Proteins